Discuss with colleagues, share knowledge, bring back to clinic - why I attend #acr15 @RheumNow @carvicab @ACRheum pic.twitter.com/bFnuA9XlPk— Dr. Antoni Chan (@synovialjoints) November 11, 2015
Since returning from the ACR 2015, I've shared my highlights with my team. This was through our Journal Club. It takes about 60 minutes to cover a session.
Here are some of my highlights from ACR 2015. I hope you may find it useful to discuss in your Journal Club or educational meetings.
You can find further details of the presentations and abstracts at the ACR 2015 website:
The posters that covered this topic were #2887, #2890, #2896, #974, #981, #6L,
ASAS 40 response at Week 52 was measured. The outcome in different groups were:
Nasopharyngitis was the commonest AE with secukinumab (11.2% vs 6.1% in placebo).
Discontinuation due to AE was 4.7% in Secukinumab and 5.6% in placebo. 3 deaths (1 suicide in placebo, 1 respiratory failure and 1 acute MI in secukinumab group)
80% of patients on Secukinumab did not show radiographic progression. Factors predicting radiographic progression were baseline syndesmophytes, male gender and elevated CRP at baseline. This showed IL-17A inhibition on structural change in AS.
Biologic naïve patients, receiving Ixekizumab 80mg q2w or q4w vs Adalimumab 40mg q2w vs placebo.
Discontinuation due to treatment emergent adverse events was similar across groups and no deaths occurred. Ixekizumab showed significant, clinically meaningful improvement in psoriatic arthritis.
The SLE Responder Index (SRI) was used as the outcome measure together with reduction in oral corticosteroid (OCS) use at days 169 and 365. The groups were divided by IFN gene signature (IFN high vs IFN low).
Anifrolumab efficacy was similar or better in the IFN high patients. The lack of dose response is due to nearly similar degress of IFN gene signature inhibition with two Anifrolumab doses.
There was a higher frequency of influenza and herpes zoster in the Anifrolumab arms. This study shows promise for IFNa inhibition in the treatment of SLE.
CD4+ T cells are depleted of a first cycle on rituximab (RTX) in patients with RA. This effect was seen in responders to RTX. This raises the possibility that CD4+ T cells levels may be linked to disease activity post RTX treatment.
Monitoring CD4+ T cells may be a useful biomarker to assess response to RTX, disease activity and further evaluation of treatment efficacy and re-treatment intervals of RTX.
(14%). Sm and Jo-1 were rare.
These are results from studies and not medical advice. Views are my own. This cannot be taken as specific medical advice and cannot replace the need to see your physician if needed for review.